Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fulgent Genetics ( (FLGT) ) just unveiled an update.
On May 21, 2026, Fulgent Genetics announced the rapid oral publication of its full abstract on FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma, which will be presented in an ASCO 2026 Head and Neck Cancer Track session on June 1 in Chicago. The abstract reports interim Phase 2 data as of December 20, 2025, showing a 60% objective response rate, median progression-free survival of 7.2 months, and a favorable safety profile compared with historical standards in this hard-to-treat population, underscoring the potential of FID-007 to strengthen Fulgent’s emerging oncology franchise.
The study evaluated two dosing regimens of FID-007 plus cetuximab in patients whose disease had progressed after PD-1-based immunotherapy, with most treatment-related adverse events being grade 1–2 and limited grade 3–4 toxicities, although one grade 5 pneumonia event occurred. While overall survival data remain immature, the early efficacy and tolerability signals suggest a potentially meaningful new option in a large global HNSCC market where current therapies deliver modest response rates and short progression-free survival, drawing investor and clinical attention to Fulgent’s therapeutic pipeline.
The most recent analyst rating on (FLGT) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
Overall score reflects a strong balance sheet and reiterated growth outlook (including expected H2 acquisition contribution) being offset by weak current profitability and sizable TTM cash burn. Technicals are mixed and valuation metrics are less supportive due to negative earnings and no dividend yield.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics, Inc. is a technology-based precision medicine company with a well-established laboratory services business and a therapeutic development arm focused on oncology. Its lab services span technical testing and physician-led interpretation, while its drug development unit uses a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetics of cancer drugs as it seeks to evolve from diagnostics into a fully integrated precision medicine player.
Average Trading Volume: 667,987
Technical Sentiment Signal: Sell
Current Market Cap: $466.1M
See more data about FLGT stock on TipRanks’ Stock Analysis page.